Sebastian Nijman
Associate Professor
Cancer is one of the biggest causes of death in the Western world. My group develops new approaches to study signalling networks in cancer cells and to uncover specific weaknesses that can be used for developing more effective targeted drugs and for guiding treatment decisions. We use high-throughput chemical and genetic screening approaches and haploid genetics to engineer isogenic human cancer cells and tease out chemical and genetic interactions that could be therapeutically exploited. These interactions are then studied in more detail using cell culture, mouse models, and patient samples.
Key publications
-
Targeting a cell state common to triple-negative breast cancers.
Journal article
Muellner MK. et al, (2015), Mol Syst Biol, 11
-
Functional genomics to uncover drug mechanism of action.
Journal article
Nijman SMB., (2015), Nat Chem Biol, 11, 942 - 948
-
Parallel reverse genetic screening in mutant human cells using transcriptomics.
Journal article
Gapp BV. et al, Mol Syst Biol, 12
-
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated.
Journal article
Smida M. et al, (2016), Nat Commun, 7
Recent publications
-
Discovery of a Highly Selective Cell-Active Inhibitor of the Histone Lysine Demethylases KDM2/7.
Journal article
Gerken PA. et al, (2017), Angew Chem Int Ed Engl, 56, 15555 - 15559